La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Entero Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che Entero Therapeutics aumenterà gli utili e i ricavi rispettivamente del 3.3% e 79.8% all'anno, mentre si prevede che l'EPS crescerà del 49.3% all'anno.

Informazioni chiave

3.3%

Tasso di crescita degli utili

49.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.0%
Tasso di crescita dei ricavi	79.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	20 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections

Jan 04

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ENTO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-42	N/A	N/A	1
12/31/2025	N/A	-32	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	2
3/31/2024	N/A	-6	-14	-13	N/A
12/31/2023	N/A	-16	-13	-12	N/A
9/30/2023	N/A	-16	-15	-15	N/A
6/30/2023	N/A	-8	-15	-15	N/A
3/31/2023	N/A	-9	-17	-17	N/A
12/31/2022	N/A	-15	-22	-22	N/A
9/30/2022	N/A	-22	-33	-23	N/A
6/30/2022	N/A	-57	-44	-34	N/A
3/31/2022	N/A	-65	-45	-35	N/A
12/31/2021	N/A	-85	-43	-32	N/A
9/30/2021	N/A	-92	-32	-32	N/A
6/30/2021	N/A	-74	-19	-19	N/A
3/31/2021	N/A	-66	-15	-15	N/A
12/31/2020	N/A	-42	-11	-11	N/A
9/30/2020	N/A	-25	-9	-9	N/A
6/30/2020	N/A	-15	-10	-10	N/A
3/31/2020	N/A	-16	-13	-13	N/A
12/31/2019	N/A	-15	-14	-14	N/A
9/30/2019	N/A	-18	-14	-14	N/A
6/30/2019	N/A	-16	-13	-13	N/A
3/31/2019	N/A	-15	-12	-11	N/A
12/31/2018	N/A	-14	-11	-11	N/A
9/30/2018	N/A	-12	-10	-10	N/A
6/30/2018	N/A	-13	-9	-9	N/A
3/31/2018	N/A	-12	-8	-8	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-14	N/A	-7	N/A
6/30/2017	N/A	-14	N/A	-7	N/A
3/31/2017	N/A	-15	N/A	-5	N/A
12/31/2016	N/A	-15	N/A	-5	N/A
9/30/2016	N/A	-10	N/A	-3	N/A
6/30/2016	N/A	-8	N/A	-4	N/A
3/31/2016	N/A	-7	N/A	-4	N/A
12/31/2015	N/A	-6	N/A	-4	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-5	N/A	-3	N/A
3/31/2015	N/A	-3	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ENTO rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ENTO rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ENTO rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che ENTO non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che ENTO non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ENTO è previsto essere elevato tra 3 anni

Entero Therapeutics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$9.00

Price target decreased to US$20.00

Price target decreased to US$25.00

No longer forecast to breakeven

Price target raised to US$4.10

Recent updates

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma Inc Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Azurrx Biopharma, Inc. Adds New Clinical Trial Sites in Ukraine for Phase 2 Reservoir Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx BioPharma Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

AzurRx BioPharma, Inc. Doses First Patient in Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

AzurRx BioPharma, Inc. announced delayed 10-Q filing

AzurRx BioPharma, Inc. Announces Positive Interim Data in Phase 2 Clinical Trial of Ms1819 in Combination with Pert in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma: An Assessment

AzurRx BioPharma, Inc. Announces Completion of Enrollment in Phase 2B Option 2 Clinical Trial of Ms1819 in Cystic Fibrosis

AzurRx BioPharma, Inc. Announces Chairman Changes

Price target raised to US$4.10

AzurRx Biopharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections